thebench.bio #1 Ecosystem for the Bio-Tech Industry

Funding Daily Summary

Funding Daily Summary: What Happened on November 13, 2026

Windward raises $225 million in IPO and Sanofi placement

Neurosterix added a $105 million Series B, while NIH outlined a new structure for clinical-trial funding announcements.

  • Updated
  • Read from 6 articles, 5 publications

Today in brief

Windward raised $225 million through a $175 million Nasdaq IPO and a separate $50 million investment from Sanofi.12 Neurosterix secured $105 million to advance its neuropsychiatric drug pipeline, including a schizophrenia candidate it plans to move into Phase 2.34

NIH is developing five clinical-trial funding announcements organized by trial type rather than disease area.5

Windward raises $225 million to fund respiratory and immune-disease drugs

Windward Bio priced about 10.3 million shares at $17 each in its Nasdaq IPO, raising $175 million.12 Sanofi committed another $50 million in a separate purchase of shares and pre-funded warrants at the IPO price.12

The financing supports two licensed candidates, including WIN378, an antibody that targets TSLP, a signaling protein involved in asthma.12 Windward aims to dose WIN378 every six months. The drug has entered the Phase 3 portion of a Phase 2/3 study in severe, uncontrolled asthma.2

Windward plans pivotal asthma studies and expects preliminary results in the first half of 2029.2 It also expects COPD data for WIN378 and Phase 1 results for WIN027 in 2027. The company estimates its cash will last into the first half of 2029.12

Neurosterix raises $105 million to develop schizophrenia and mood-disorder drugs

Neurosterix raised $105 million in a Series B led by RTW Investments. Janus Henderson Investors, GV and Acorn Bioventures also participated.3

The company plans to advance NTX-253, an oral drug designed to amplify signaling through the muscarinic M4 receptor, into Phase 2 for schizophrenia.34 Neurosterix said it completed Phase 1 studies in healthy volunteers and people with stable schizophrenia in October. Pharmacokinetic results support once-daily dosing, the company said.4

The studies have not demonstrated clinical efficacy, Neurosterix said.4 The financing will also support NTX-819 for mood and anxiety disorders and NTX-529 for psychosis and mood-related conditions.34

NIH is preparing five trial-type funding announcements

The National Institutes of Health is developing five shared clinical-trial funding announcements grouped by trial design rather than disease.5 The categories will cover feasibility, early-to-definitive, multisite, pragmatic and implementation, and network trials, according to NIH.5

NIH says the announcements should standardize guidance for similar studies and help researchers identify suitable funding routes.5 They will supplement existing broad R01 and R21 announcements and roll out in stages. Institutes can still issue targeted trial calls when needed.5

Elizabeth Ginexi warned that fewer targeted calls could weaken funding signals for overlooked research areas. Granted AI said new investigators may find it harder to identify the right submission route.5

Also worth knowing

  • Five neurology-focused startups raised about $450 million combined in recent weeks.6

Also published